We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Menlo Park, California-based Intersect ENT with a Form 483 over serious violations at its facility, including problems with environmental monitoring. Read More
The FDA hit Vida International’s drug manufacturing facility in Taoyuan City, Taiwan with a warning letter for serious quality violations including inadequate drug testing. Read More
The FDA cited bulk drug and dietary supplement manufacturer PLD Acquisitions following a Jan. 17-30 inspection of its Doral, Florida facility that turned up multiple equipment cleaning and maintenance issues. Read More
The FDA issued a warning letter to Spectrum Laboratory Products’ Gardena, California facility for releasing adulterated and misbranded drugs. Read More
The FDA issued a warning letter to Pharmasol over violations at two of its drug manufacturing facilities, including problems with quality oversight and leaky stability samples. Read More